Detail akcie Mode online

Business Summary: Sygnis SA is a Poland-based company primarily engaged in the Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Sygnis SA revenues increased from PLN221K to PLN2M. Net loss increased from PLN588K to PLN2.2M. Revenues reflect Sales of Products increase from PLN205K to PLN1.4M, Sales of Goods and Materials increase from PLN16K to PLN562K. Higher net loss reflects Outsoursing increase from PLN262K to PLN751K (expense), Property & Other Taxes increase from PLN4K to PLN114K (expense).